Claiming not to be in competition with each other but rather with time and the coronavirus, top executives from the world’s leading pharmaceutical companies said yesterday they’re working as fast as they can to develop, scale up, and distribute a COVID-19 vaccine. At a media briefing organized by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), executives from AstraZeneca, GlaxoSmithKline, Johnson & Johnson, and Pfizer also said they were committed to making coronavirus vaccines safe and ensuring equitable access. “We are deeply aware that no one can fight COVID-19/SARS-CoV-2 on their own,” said IFPMA Director General Thomas Cueni, MS. “The industry is all in.” “As we all know, we need a lot of options, as soon as possible,” said Albert Bourla, DVM, PhD, chairman and CEO of Pfizer, which has an mRNA vaccine candidate with German company BioNTech currently in phase 1 trials in Europe and the United States. Pfizer, Johnson & Johnson, and AstraZeneca are among a handful of companies currently working on a vaccine for the coronavirus, which has sickened more than 5.9 million people worldwide and killed more than 358,000. According to the World Health Organization (WHO), there are more than 10 candidates in clinical evaluation and 115 in preclinical evaluation. Public health officials agree that the COVID-19 pandemic won’t end until a vaccine, or several, are available.

 

Credit: iStock, gevende

Read more CIDRAP…